Andera Partners

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Andera Partners reported 5 stock positions worth $176.6 million. Its top holding was Kestra Medical Technologies (KMTS) at 38.1% of the portfolio, followed by Mineralys Therapeutics (MLYS, 32.7%) and Evommune (EVMN, 18.4%).

Most Recent 13F
Q2 2026
Location
PARIS, I0
CIK
0001757283
Portfolio Value
$176.6M (Q4 2025)
SEC Filing
0001757283-26-000007 ↗ filed Feb 17, 2026

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q4 2025: $176.6M $176.6M Q4 2025 Q1 2026: $176.9M Q1 2026 Q2 2026: $206.5M Q2 2026

Holdings 5 stocks · $176.6M
KMTS Kestra Medical Technologies 38.14% 2,540,106 $67.4M —
MLYS Mineralys Therapeutics Inc. 32.71% 1,591,917 $57.8M —
EVMN Evommune Inc. 18.39% 1,897,362 $32.5M —
ABVX Abivax SA-ADR 5.97% 78,125 $10.5M —
IVA Inventiva SA - ADR 4.79% 1,818,181 $8.5M —

Portfolio Sells Q4 2025

No earlier filing to compare with.

Portfolio Buys Q4 2025

No earlier filing to compare with.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 8$206.5MKMTS, MLYS, AVLN, AGMB, EVMN
Q1 2026 7$176.9MKMTS, EVMN, MLYS, AGMB, IVA
Q4 2025 5$176.6MKMTS, MLYS, EVMN, ABVX, IVA